Synthetic Antibiotic Cipro Used For Treatment Of Urinary Tract Infections Legionellosis Mycobacteria

Ciprofloxacin points out to the generic name that exists on an international level for the synthetic antibiotic. It’s manufacturing as well as marketing is the responsibility of Bayer A.G. carrying the brand names as Ciproxin, Cipro as well as Ciprobay.

It is bacteriocidal and the mode of action of this antibiotic is based on overcrowding bacterial DNA replication by the process of fastening itself to an enzyme namely DNA gyrase and hence leads to stranded breaks turning up in the bacterial chromosome. Cipro is regarded as a broad-spectrum antibiotic that actively reacts against Gram-positive as well as Gram-negative bacteria.

Cipro works through the inhibition of DNA gyrase, which is a kind of type II topoisomerase as well as an enzyme required for the purpose of dividing, replicated DNA and hence inhibits cell division. It is found to be of quite a lot of use against Vibrio, Pseudomonas aeruginosa, Haemophilus influenzae, Mycobacterium intracellulare, Moraxella catarrhalis, Bacillus anthracis, Neisseria gonorrhoeae and many more. It comes with a weak performance against Chlamydia pneumoniae, Streptococcus pneumoniae as well as Chlamydia trachomatis.

Cipro displays no activity against Ureaplasma urealyticum, Bacteroides, Streptococcus pyogenes, Burkholderia cepacia and Enterococcus faecium. One of the biggest side effects that are discovered on its application is gastrointestinal irritation which is popular with many other antibiotics as well. It was kept in the form of a drug of last resort owing to its power, safety as well as broad spectrum performance to be put to application on infections that are comparatively complex and antibiotic-resistant.

It is used for providing treatment for the infection with mycoplasma in cell culture. This drug can be used for topical and oral needs. The dosage that is given in Respiratory tract infection measures 500-1500 mg on each individual day in 2 doses. It also finds application in urinary tract infections, lower respiratory infections, Legionellosis, STDs, Mycobacteria as well as septicemias.

The U.S. Food and Drug Administration in the year 2005 turned up with the alteration of the package insert for Cipro for providing acknowledgement in relation to formation of irreversible neurological conditions as well as the tendon ruptures. Cipro